ArticleAdvances in therapy2025
Prurigo Nodularis PaTient-Reported BurdEn of SicKness (PN TREK): A Cross-Sectional Survey of Patient-Reported Burden of Disease in Patients with PN from the US.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study assessed the comprehensive disease burden, the correlation among different patient-reported outcome measures (PROMs), and patient-reported treatment satisfaction with non-biologic agents in adult patients with prurigo nodularis (PN) in the United States.
methodsA patient survey was conducted in the United States from June 30 to October 6, 2022, in patients with a self-reported diagnosis of PN. The survey included different PROMs assessing the symptoms and impacts of PN. The t test, chi-square test, Fisher's exact test, Spearman correlation, and Kendall correlation analysis were performed where applicable.
resultsA total of 132 patients participated in the survey. Approximately 46%, 34%, and 20% of patients reported a worst itch-numeric rating scale (WI-NRS) score of ≥ 7, 3-6, and 0-2, respectively. Assessment of PROMs revealed that patients with a WI-NRS score of ≥ 7 (vs. 0-2) experienced more severe skin pain, neurological pain, greater negative impacts on quality of life (QoL), sleep disturbance, mental health, and work productivity and activity impairment (WPAI), as well as higher health care resource utilization (HCRU) (all p < 0.001). The proportion of patients satisfied with non-biologic treatment was significantly lower in patients with WI-NRS ≥ 7 (23.0% vs. 80.8% in WI-NRS 0-2). WI-NRS, Patient Global Impression of Severity (PGIS), average itch-NRS, and Dermatology Life Quality Index (DLQI) were strongly positively correlated (r ≥ 0.5) with each other and negatively correlated with Patient Global Assessment (PtGA) (r < - 0.5), while the number of nodules had weak correlations (absolute r < 0.3) with all PROMs except PGIS (r = 0.403) and PtGA (r = - 0.327).
conclusionIn patients with PN, severe itching is associated with an increased symptom burden, greater disease impact, along with reduced satisfaction with non-biologic treatments. Additionally, the number of nodules alone may not adequately describe disease severity in patients with PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.